WO2015150394A1 - Agent cryoprotecteur, compositions cryoprotectrices et cryoconservées, leurs utilisations et procédés de cryoconservation - Google Patents

Agent cryoprotecteur, compositions cryoprotectrices et cryoconservées, leurs utilisations et procédés de cryoconservation Download PDF

Info

Publication number
WO2015150394A1
WO2015150394A1 PCT/EP2015/057047 EP2015057047W WO2015150394A1 WO 2015150394 A1 WO2015150394 A1 WO 2015150394A1 EP 2015057047 W EP2015057047 W EP 2015057047W WO 2015150394 A1 WO2015150394 A1 WO 2015150394A1
Authority
WO
WIPO (PCT)
Prior art keywords
cryoprotectant
cells
sample
cryoprotective agent
carboxyalkyldextran
Prior art date
Application number
PCT/EP2015/057047
Other languages
English (en)
Inventor
Hans Berg Andreasen
Lars Christensen
Kim NORDFJELD
Jeppe SKYTTE
Christian Clausen
Bjørn HOLST
Tobias Sidelmann CHRISTENSEN
Original Assignee
Pharmacosmos A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacosmos A/S filed Critical Pharmacosmos A/S
Publication of WO2015150394A1 publication Critical patent/WO2015150394A1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02Preservation of living parts
    • A01N1/0205Chemical aspects
    • A01N1/021Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0221Freeze-process protecting agents, i.e. substances protecting cells from effects of the physical process, e.g. cryoprotectants, osmolarity regulators like oncotic agents

Definitions

  • the present invention relates to a cryoprotectant, a cryoprotective agent, cryoprotective compositions, cryopreserved compositions, uses thereof, and methods of cryopreservation.
  • Cryopreservation of viable biological samples such as cells, tissues or organs, which have been harvested from a donor source is of great importance and utility in the scientific and medical communities.
  • Cryopreservation techniques are routinely used for long-time preservation of water-bearing or aqueous materials such as cells and tissues of plants and animals. It is known that upon freezing these materials, ice crystals form, resulting in uneven concentrations of solutes and contaminants excluded by water molecules, called “freeze concentration".
  • cryoprotectant solutions are typically used to prevent damage due to freezing during the cooling or thawing process.
  • the preserved sample should retain its integrity and viability to a reasonable level at the time of harvest.
  • the process of preserving the sample should preferably not, in itself, severely damage or destroy for example the cells or tissue architecture.
  • the sample is harvested, placed in a storage solution, and then preserved by freezing.
  • the sample is thawed, and, as an example, cells taken from human donor sources are brought back to the normal human body temperature (i.e., approximately 37°C) and then placed in a cell culture medium.
  • Cryopreservation protocols subject the cells to a multitude of stresses and perturbations throughout the process of cell harvesting, freezing, and thawing. These stresses and perturbations can cause irreversible damage to the cell.
  • Dextran has been used as a cryoprotective agent for human, animal and plant cells (Odavic, R. et al. Experientia 36, 1122 (1980), Ashwood-Smith, M.J. et al. Cryobiology 9, 441 (1972) and Echlin, P. et al . J. Microsc. (Oxford) 110, 239 ( 1977) ) .
  • a mixture of 5% methyl sulphoxide and 9% Dextran 70 was found to afford optimal cryoprotection of human bone marrow committed stem cells (Dextran, Handbook from Amersham Biosciences, 18- 1166- 12, Edition AA, page 35) .
  • Dextran, glycerol and dimethyl sulfoxide (DMSO), alone or in combination, have been investigated for cryoprotection of human bone marrow cells (Odavic, R. et al . Experientia 36, 1122 ( 1980)) .
  • a significantly better protection against freezing injury was obtained by 9% Dextran 70 in combination with 3 or 5% DMSO, and also with 5 or 10% DMSO alone, than with either 15% glycerol or 9% dextran with 1% DMSO.
  • Dextran 40 is known (Proc. Nati . Acad . Sci . USA, Vol . 92, pp. 10119- 10122, October 1995, Medical Sciences) for cryopreservation of placental/umbilical cord blood in a combination of 50% DMSO in 5% (w/v) Dextran 40.
  • fructooligosaccharide isomaltooligosaccharide or galactooligosaccharide for surimi .
  • a cryoprotectant of fructooligosaccharide, isomaltooligosaccharide and galactooligosaccharide on beef protein is described .
  • Conventiona l cryoprotectants are glycols (alcohols contain ing at least two hydroxyl groups), such as ethylene glycol, propylene glycol, a nd glycerol .
  • Ethylene glycol is commonly used as automobile antifreeze, and propylene glycol has been used to reduce ice formation in ice cream .
  • Dimethyl sulfoxide (DMSO) is also regarded as a conventional cryoprotectant.
  • Glycerol and DMSO have been used for decades by cryobiologists to reduce ice formation in sperm and embryos that are preserved in liquid nitrogen (- 196° C) .
  • DMSO is considered the most effective and frequently adopted, but it is physiological ly toxic and known to cause high blood pressure, nausea and vomiting if transfused to a recipient with the cells or for personnel handling it unless precautions are taken .
  • Cox et a l (Cell Tissue Bank (2012) 13 : 203-215) identified by a retrospective review of published literature several hundred adverse reactions (e.g . nausea, chil ls, cardiac arrhythmias, neurological symptoms and respiratory arrest) associated with the
  • DMSO dimethyl sulfoxide
  • cryoprotectant as a replacement for other cryoprotectants such as DMSO or as a supplement to such other cryoprotectants to reduce the concentration thereof, preferably to non-toxic concentrations, or to improve the function thereof, said cryoprotectant having the necessary protective effects with regard to preserving as much functionality such as survival or viability after thawing of the
  • cryopreserved sample during cryopreserving It is a further object of embodiments of the invention to provide a cryoprotectant having a low or no toxicity for the personnel handling the cryoprotectant and for the biological samples, whereby the time that the sample can be in contact with the cryoprotectant without being damaged is prolonged, the necessity for washing of samples is reduced, and, if desired, making it possible to return the sample to where it was taken from or to a recipient without having to separate the sample from the cryoprotectant.
  • cryoprotectant said cryoprotectant being effective as a cryoprotectant for a sample selected from the group consisting of organs, cells and tissues such as selected from the group consisting of mammalian organs, mammalian cells, and mammalian tissues. It is a further object of embodiments of the invention to provide a cryoprotectant, said cryoprotectant being effective as a cryoprotectant for a sample to be transplanted such as an organ, cells or tissues.
  • cryoprotectant said cryoprotectant being effective as a cryoprotectant of for example cells and result in an acceptable viability of said cells such as survival or viability after thawing. It is a further object of embodiments of the invention to provide a cryoprotectant, said cryoprotectant being effective as a cryoprotectant of for example organs and result in an acceptable physical functionality of said organs. It is a further object of embodiments of the invention to provide a cryoprotectant, said cryoprotectant being effective as a cryoprotectant of for example tissues and result in an acceptable physical functionality of said tissues.
  • a cryoprotective agent comprising a cryoprotectant selected from the group consisting of carboxyalkyldextran, hydrogenated carboxyalkyldextran, oxidated carboxyalkyldextran, ether of carboxyalkyldextran, ester of carboxyalkyldextran and partly oxidated/hydrogenated carboxyalkyldextran or a combination thereof, is very useful as a cryoprotectant.
  • the cryoprotectant is very useful as a cryoprotectant.
  • the cryoprotectant is
  • cryoprotectant is hydrogenated
  • the present invention relates to the use of a cryoprotectant as described herein for cryopreserving a sample, and wherein said sample is selected from the group consisting of organs, cells, and tissues.
  • the present invention relates to a cryoprotective agent comprising a cryoprotectant as described herein.
  • the present invention relates to the use of a cryoprotectant as described herein for cryopreserving a sample, wherein said sample is selected from the group consisting of organs, cells and tissues.
  • the present invention relates to a cryopreservation composition
  • a cryopreservation composition comprising a cryoprotective agent as described herein, which cryopreservation composition further comprises a sample to be cryopreserved, wherein said sample is selected from the group consisting of mammalian organs, mammalian cells, and mammalian tissues.
  • the present invention relates to a cryopreserved composition
  • a cryopreserved composition comprising a cryoprotective agent as described herein, which cryopreserved composition further comprises a sample to be cryopreserved.
  • Said sample may be selected from the group consisting of mammalian organs, mammalian cells, and mammalian tissues.
  • the present invention relates to a method of cryopreserving a sample, comprising the steps of bringing a sample to be cryopreserved into contact with a cryoprotective agent as described herein to obtain a cryopreservation composition and subsequently reducing the temperature of the cryopreservation composition to a
  • cryopreservation temperature Said sample may be selected from the group consisting of organs, cells and tissues.
  • the present invention relates to a method of cryopreserving a cryopreservation composition as described herein by bringing the composition to a cryopreservation temperature.
  • the present invention relates to the use of a cryoprotective agent as described herein for cryopreserving a sample, wherein said sample is selected from the group consisting of organs, cells and tissues.
  • the present invention relates to the use of a cryoprotective agent as described herein for cryopreserving a sample for transplantation.
  • the present invention relates to the use of a cryopreservation
  • the Figures show human induced pluripotent stem cells (abbreviated iPSCs or iPS cells) which were cryopreserved and thawed in the cryopreservation compositions described in example 1 and 2. Viability after thawing (Fig. 1, Fig. 3 and Fig. 6) and the proliferative rate of the cells (Fig. 2 and Fig. 4) were evaluated.
  • the figures demonstrate a clear positive effect of including hydrogenated carboxymethyldextran relative to the untreated sample.
  • cryopreservation means a process where a sample is preserved by cooling to sub-zero temperatures, including vitrification technology in which the cooling rate is faster than a conventional cryopreservation procedure. At such low temperatures activity such as biological activity, including the biochemical reactions that would cause for example cell death, are reduced, and the chemical structure/function of for example proteins/glyco- proteins or lipoproteins are preserved. If cryoprotectant solutions are not used, the samples being preserved are likely to be damaged due to freezing during the cooling or thawing process.
  • cryopreservation temperature designates a temperature of from sub-zero to -196 °C, such as from - 50 °C to -196 °C, such as from - 80 °C to -196 °C, such as a temperature below -55 °C, such as below -60 °C, such as below -65°C, such as below - 70 °C, such as below -75 °C, such as below -80 °C, such as below -85 °C, such as below -90 °C, such as below -95 °C, such as below -100 °C, such as below -105 °C, such as below -110 °C, such as below -115 °C, such as below -120 °C, such as below -125 °C, such as below - 130 °C, such
  • sample means any kind of material to be cryopreserved such as organs, cells, or tissue.
  • a sample is selected from the group consisting of organs, cells, tissue and blood.
  • a sample is selected from the group consisting of organs, cells, and tissue, such as selected from the group consisting of mammalian organs, mammalian cells and mammalian tissues.
  • the term "sample” does not comprise the human body at the various stages of its formation and development.
  • the present invention relates to the use of a cryoprotective agent as described herein for cryopreserving a sample for transplantation.
  • the sample is selected from the group consisting of mammalian organs, mammalian cells and mammalian tissues for transplantation.
  • the term "cells” comprises any type of cells such as somatic cells including all kind of cells in tissue or organs, stem cells including all types of totipotent stem cells, pluripotent stem cells, multipotent stem cells and progenitor cells; oocytes; spermatozoa; and germ cells.
  • the cells may be in isolated form or in a not isolated form such as in the form of a cell-containing bodily fluid, a tissue or organ.
  • the term “cell-containing bodily fluids” comprises any cell-containing bodily fluid such as for example below defined blood, amniotic fluid, semen, cerebrospinal fluid, bone marrow aspirates and menstrual fluid.
  • blood comprises any blood containing fluid such as umbilical cord blood, peripheral blood, and mobilized blood.
  • tissue or “tissues” comprises any tissue type comprising any kind of cell type and combinations thereof, including ovarian tissue, testicular tissue, umbilical cord tissue, placental tissue, connective tissue, cardiac tissue, tissues from muscle, cartilage and bone, endocrine tissue, and neural tissue.
  • tissue or “tissues” also comprise adipose tissue or dental pulp tissue.
  • organ comprises for example lung, liver, kidney, heart, ovaries and pancreas.
  • organ also comprise umbilical cord.
  • the term "functional after cryopreservation" in relation to a sample means that the sample such as organs, tissue or cells after cryopreservation retains an acceptable and/or desired function after cryopreservation.
  • the sample after cryopreservation retains an acceptable and/or desired function after cryopreservation.
  • cryopreservation retains all its function.
  • the sample such as cells
  • at least retains 50% of the desired function such as at least 60% of the desired function, such as at least 70% of the desired function, such as at least 80% of the desired function, such as at least 90% of the desired function, such as at least 95% of the desired function, such as 100% of the desired function
  • the desired function such as at least 60% of the desired function, such as at least 70% of the desired function, such as at least 80% of the desired function, such as at least 90% of the desired function, such as at least 95% of the desired function, such as 100% of the desired function
  • the desired function such as at least 60% of the desired function, such as at least 70% of the desired function, such as at least 80% of the desired function, such as at least 90% of the desired function, such as at least 95% of the desired function, such as 100% of the desired function
  • the desired function such as at least 60% of the desired function, such as at least 70% of the desired function, such as at least 80% of the desired function, such as
  • the viability of cells after cryopreservation may be measured by using the Nucleocounter system in which dead cells are measured by incubating the cell sample with the DMA binding dye, propidium iodide, which only results in detectable measurement from dead cells as shown in the examples.
  • the viability is given as a percentage of living cells in the population that are being analyzed.
  • the proliferative rate of a cell sample after cryopreservation can be analysed using the colorimetric assay, MTT.
  • banking means any storage of a sample for future use.
  • clinical banking method means any storage of a sample relating to clinical treatment of a mammal such as a human being.
  • marrow banking method means storage of a marrow sample such as bone marrow aspirates and related bodily fluid, or cells isolated from marrow.
  • marrow tissue banking method means storage of a dental pulp tissue sample such as cells isolated from dental pulp tissue.
  • fat tissue banking method means storage of a fat tissue sample such as cells isolated from fat tissue.
  • umbilical cord banking method means storage of umbilical cord blood, tissues related to umbilical cord or cells isolated from umbilical cord blood or tissue.
  • mobilized peripheral blood banking method means storage of peripheral blood after mobilizing with agents that for example releases blood stem cells into the circulation.
  • production banking method means storage of any sample relating to reproduction such as semen, oocytes, spermatozoa, fertilized eggs etc.
  • the atomic mass unit Dalton (symbol: Da) is the standard unit used for indicating mass on an atomic or molecular scale (atomic mass). It is defined as one twelfth of the remaining mass of an unbound neutral atom of carbon-12 in its nuclear and electronic ground state.
  • weight average molecular weight (M w ) is defined as:
  • g is the fraction of molecules having the molecular weight M,.
  • M is the fraction of molecules having the molecular weight M,.
  • the possible values of M make up a set of numbers with discrete values labelled if defining p.
  • number average molecular weight is defined as:
  • N is the fraction of molecules having the molecular weight M i( g ⁇ is the fraction of molecules having the molecular weight M,.
  • the possible values of M make up a set of numbers with discrete values labelled ,, defining p.
  • polydispersity Pd.
  • Dextran As used herein, the term “Dextran” followed by a number such as “Dextran 1", “Dextran 40” and “Dextran 70” follows the Pharmacopoeial abbreviation for Dextran X meaning that the weight average molecular weight of the dextran is approximately X kDA.
  • Dextran 1 means a dextran having a weight average molecular weight of 850- 1, 150 Da.
  • Isomaltooligosaccharide 1 and hydrogenated isomaltooligosaccharide 1 are named similarly.
  • Isomaltooligosaccharide 1 means thus a mixture of isomaltooligosaccharides having a weight average molecular weight of 850- 1, 150 Da conforming to the EP and USP Monographs for Dextran 1.
  • Isomaltooligosaccharide 1 is also named pentaisomaltose in this application .
  • Hydrogenated isomaltooligosaccharide 1 means a mixture of hydrogenated
  • isomaltooligosaccharides where the isomaltooligosaccharides conforms to the EP and USP Monographs for Dextran 1.
  • Hydrogenated isomaltooligosaccharide 1 is also named pentaisomaltoside in this application .
  • isomaltooligosaccharide having a weight average molecular weight (M w ) of between 300 and 1,650 Da, such as between 850 and 1,650 Da and obtained from hydrolysed dextran such as by hydrolysis of low molecular weight dextran.
  • M w weight average molecular weight
  • cryoprotectant means a substance which for example In an appropriate solution is used to protect a sample from freezing damage.
  • cryoprotectants are for example DMSO, polyols etc.
  • sterile means free from living germs, microorganisms and other organisms capable of proliferation.
  • substantially free of DMSO means DMSO in an amount less than O.Olw/w %.
  • Ci- 10 alkyl is a hydrocarbon being a straight-chain or branched Cj. 10 alkyl such as a straight-chain or branched Ci- 6 alkyi. Examples are methyl, ethyl, 1-propyl, 2- propyl, isopropyl, 1-butyl, 2-methyl- l-propyl, 2-butyl, 1-pentyl, 3-pentyl, 2-methyl-2-butyl, and 3-methyl-2-butyl.
  • carboxyCi- 10 alkyl means -Ci. 10 alkylCOOH. An example is carboxymethyl
  • DEAE diethylaminoethyl
  • hydrochlorinated carboxyalkyidextran means hydrogenated dextran substituted with carboxyalkyl.
  • oxidated carboxyalkyidextran means oxidated dextran substituted with carboxyalkyl.
  • cryoprotective agent comprising a cryoprotectant selected from the group consisting of carboxyalkyidextran, hydrogenated carboxyalkyidextran, oxidated ca rboxya I ky Idextra n , ether of carboxyalkyidextran, ester of carboxyalkyidextran and partly oxidated/hydrogenated carboxyalkyidextran or a combination thereof, such as
  • Dextran comprises repeating D-glucose units.
  • Dextrans are a family of neutral branched polysaccharides consisting predominantly of an a-(l ⁇ 6) linked D-glucose as further described below.
  • the carboxyalkyidextran is carboxyCi. 10 alkyidextran.
  • the C x i 0 alkyl is suitably methyl.
  • the cryoprotectant is carboxymethyl
  • the molecular weight of dextran is typically determined by means of gel permeation chromatography (GPC) using for example GPC columns of the type polyether hydroxylated gels.
  • GPC gel permeation chromatography
  • cryoprotectant described herein is selected from the group consisting of carboxyalkyidextran, hydrogenated carboxyalkyidextran, oxidated carboxyalkyidextran, ether of carboxyalkyidextran, ester of carboxyalkyidextran and partly oxidated/hydrogenated carboxyalkyidextran or a combination thereof such as carboxyalkyidextran and has a weight average molecular weight (Mw) of between 300 and 900,000 Da such as between 300 and 700,000 Da, preferably between 300 and 500,000 Da.
  • Mw weight average molecular weight
  • the cryoprotectant described herein has a weight average molecular weight (Mw) of above 700,000 Da such as between 700,000 and 900,000 Da. In one aspect, the cryoprotectant described herein has a weight average molecular weight (Mw) of between 500 and 15,000 Da such as between 500 and 6000 Da. In a further aspect, the cryoprotectant described herein has a weight average molecular weight (Mw) of between 500 and 1500 Da or between 3000 and 6000 Da .
  • the cryoprotectant described herein is hydrogenated carboxyalkyldextran and has a weight average molecular weight (Mw) of 300 and 900,000 Da such as between 500 and 15,000 Da, or such as between 500 and 6000 Da .
  • the hydrogenated ca rboxya I ky Idextra n described herein has a weight average molecular weight (Mw) of between 500 and 1500 Da or between 3000 and 6000 Da. In some aspects, the average molecular weight (Mw) is above 700,000 Da.
  • the hydrogenated cryoprotectant described herein has a weight average molecular weight (Mw) of between 700,000 and 900,000 Da.
  • the cryoprotectant as described herein may be prepared by using hydrogenated dextran or hydrogenated isomaltooligosaccharide or the corresponding polysaccharide having a weight average molecular weight (Mw) of between 300 and 900,000 Da such as between 1000 Da to 700,000 Da as a starting material.
  • the starting material has a weight average molecular weight (Mw) of between 1000 and 7000 Da, such as between 1650 and 6000 Da, such as between 2000 and 5000 Da .
  • the starting material suitably has a polydispersity of > 1 and ⁇ 5.
  • the cryoprotective agent having a lower average molecular weight Compared to dextran materials of higher average molecular weight such as Dextran 40 (40,000 Da) and Dextran 70 (70,000 Da), the cryoprotective agent having a lower average molecular weight have a lower viscosity. This facilitates preparation of a high concentration, making it possible to add a sample already in a solution and still obtain a composition comprising both cryoprotectant and sample in a concentration suitable for cryopreservation. Furthermore, within the described class of molecules, molecules with lower molecular weight are generally less immunogenic than molecules with high molecular weight.
  • Dextran 1 is for example known as a hapten inhibitor that reduces the risk for anaphylactic reactions when administering dextran and is thus used as pre-injection before injection of d extra ns with higher molecular weight such as Dextran 40 (40,000 Da) and Dextran 70 (70,000 Da).
  • Dextran 1 has also been documented in studies by Richter et al (Int. Arch. Allergy 43 : 252-268 ( 1972) and Int. Arch . Allergy 41 : 826-844 ( 1971)) to have a very low immunological potential in humans.
  • the cryoprotectant according to the invention suitably has a content of carboxy groups of above 1 % w/w, such as above 2.0 % w/w, such as above 3 % w/w, such as above 4 % w/w, such as for example between 1-7.0 % w/w/, such as between 3-7 % w/w or between 4-7% w/w, as determined by direct titration using for example sodium hydroxide.
  • the cryoprotectant according to the invention suitably has a content of carboxy groups of between 1- 15 % w/w, such as between 5-12 % w/w, as determined by direct titration using for example sodium hydroxide.
  • the degree of substitution may be measured as described below through titration of the cryoprotectant in its acidic form: x. ⁇ . ⁇ n/ AxN NaOH xl00xM
  • A amount of used NaOl 1 in mL
  • Dextran can be formed by several bacterial strains, mostly gram-positive, facultative anaerobe cocci, e.g. Leuconostoc and Streptococcus strains as for example described in "Advances in polymer science", Volume 205, Polysaccharides II, editor D.KIemm, Springer Verlag.
  • Dextrans for pharmaceutical use have typically been manufactured by specific bacterial strains defined in the US or European Pharmacopoeias such as for example by Leuconostoc Mesenteroides NCTC 10817 or B512 F.
  • the strain NCTC 10817 and B512F is publicly available since 1971 from National Collection Type Cultures (Central Public Health Laboratory) UK,
  • Dextrans are a family of neutral branched polysaccharides consisting predominantly of an a- (1 ⁇ 6) linked D-glucose having a main chain with varying proportions of linkages and branches depending on the bacteria used in the fermentation.
  • the dextran molecule contains one free terminal aldehyde group which is not shown in Formula I.
  • the o-(l ⁇ 6) linkages in dextran may vary from 50 to 97 % of the total glucosidic bonds.
  • the remaining glucosidic bonds represent a-(l ⁇ 2), a-(l ⁇ 3) and a-(l ⁇ 4) linkages bound as branches.
  • Formula I illustrates part of the a-( l ⁇ 6)- linked glucose main chain of dextran with branching points in 2-, 3- and 4- positions. Using the abovementioned strain B512F the ratio of a-(l-6) linkages ist typically 95 % or above.
  • Dextrans for pharmaceutical use have typically been manufactured by specific bacterial strains defined in the US or European Pharmacopoeias such as for example by Leuconostoc Mesenteroides NCTC 10817 or B512 F.
  • the strain B512F and NCTC 10817 is as mentioned above both publicly available from National Collection Type Cultures (Central Public Health Laboratory) UK.
  • Dextran 40 and Dextran 70 have been used for human pharmaceutical use.
  • Other molecular sizes such as e.g. Dextran 500 and Dextran 5 and molecular weights in between are used outside the area of cryopreservation as carriers for synthesis, for separation of cells, as excipients in vaccines or in various other applications such as preservation of the human cornea.
  • Dextran 1 has a special use in humans as pre-injection of Dextran 1 exhibits hapten-inhibition and blocks human dextran antibodies, thus preventing potential allergic reactions known to occur occasionally after administration of high molecular weight dextran in humans.
  • Dextran 1, Dextran 40 and Dextran 70 are well described Pharmacopoeia products (European Pharmacopoeia 7 th Edition, volume 2, page 1816-1819).
  • Dextran is also an excellent raw material used for synthesizing water-soluble polymers.
  • Hydrogenated dextran which may be synthesised by reaction of dextran with a reducing agent such as borohydride under alkaline conditions for example at pH 8-12 reducing aldehyde end groups into sorbitol.
  • a reducing agent such as borohydride under alkaline conditions for example at pH 8-12 reducing aldehyde end groups into sorbitol.
  • Ethers of dextran which may be synthesies by methods known to the skilled person.
  • DEAE dextran 2-(Diethylamino)ethyl dextran
  • Reaction scheme 1 2-(Diethylamino)ethyl dextran (DEAE dextran) (shown in Reaction scheme 1) which may be synthesised by reaction of dextran with (2- chloroethyl)diethylammonium chloride in alkaline solution.
  • Reaction scheme 1 DEAE dextran containing 2-(diethylamino)ethyl (A) and 2- [(2-
  • CarboxyC 1-10 aSkyi dextran such as carboxymethyldextran (CMD) as shown in Reaction Scheme 2 may be synthesised by reaction with monochloric acetic acid (MCA) under strong alkaline conditions.
  • the carboxyalkyldextran has a content of carboxy groups of above 1 % w/w, such as above 2.0 % w/w, or such as above 3 % w/w, such as above 4 % w/w, such as for example 1-7.0 % w/w or such as 4-7% w/w determined by direct titration using for example sodium hydroxide.
  • Esters of dextran such as dextran acetate which may be synthesised by reaction of dextran with acetic acid anhydride.
  • Oxidated dextran may for example be synthesised by means of a sodium hypochlorite in a basic aqueous solution.
  • the hydrogenation is only partial, leaving at the most 15% by weight reducing sugar, calculated on the total amount of carbon hydrates, and said dextran is subsequently subjected to oxidation, said hydrogenation and oxidation being performed to obtain dextran having substantially all aldehyde groups converted into alcohol and carboxylic groups, and said dextran product having no functional aldehyde groups or functional carboxylic acid groups in the intermediate glycosyl groups; wherein the hydrogenation is performed by means of sodium borohydride in aqueous solution; and wherein the oxidation is performed by means of a sodium hypochlorite in basic aqueous solution.
  • CarboxyCi-jo alkyl-substituted of above hydrogenated and/or oxidated dextran may be prepared by methods known to the skilled person similar to the above described for example as described in the preparation examples herein. Isomaltooligosaccharide and derivatives thereof
  • Isomaltooligosaccharides are glucose oligomers with an a-D-(l,6)- bound main chain.
  • the isomaltooligosaccharide described herein is dextran-based and is made by hydrolysis of low molecular weight dextran.
  • the isomaltooligosaccharide described has a weight average molecular weight (M w ) of between 300 and 1,650 Da such as having a weight average molecular weight (M w ) of between 850 and 1,650 Da.
  • the isomaltooligosaccharide described herein is hydrolysed dextran having a weight average molecular weight (M w ) of between 850 and 1,650 Da.
  • isomaltooligosaccharide derivatives thereof characterised by the changing of the reducing aldehyde end groups into glycitol/sorbitol may be prepared.
  • the conversion from isomaltooligosaccharide to hydrogenated isomaltooligosaccharide may be performed by treating the isomaltooligosaccharide with a reducing agent, such as e.g. borohydride under alkaline conditions as shown in below Reaction scheme 4:
  • carboxyalkyl derivatives of isomaltooligosaccharide may also be made by reaction with for example monochloroacetic acid (MCA) for synthesising carboxymethyl isomaltooligosaccharide.
  • MCA monochloroacetic acid
  • oligo-isomaltose characterized by a complete lack of branching side-chains a-(l ⁇ 2), a-( l ⁇ 3) and a-(l ⁇ 4) defining the dextran molecules.
  • oligoisomaltose is considered as a subset of isomaltooligosaccharide.
  • oligoisomaltose has a weight average molecular weight (Mw) of between 300 and 1,650 Da such as between 850 and 1,650 Da, preferably between 850 and 1,150 Da, and having a complete lack of branching side-chains a-(l ⁇ 2), a-(l ⁇ 3) and a-(l ⁇ 4).
  • Mw weight average molecular weight
  • isomaltooligosaccharide can be performed using oligo-isomaltose.
  • cryoprotectant is sterile, and that other optional components of the cryopreservation agent/composition also are sterile.
  • cryoprotectant as described herein such as carboxyalkyldextran cryoprotectant with an additional cryoprotectant in order to reduce the concentration of such additional cryoprotectant, preferably to non-toxic concentrations. This may be particular useful for specific cell types, like hepatocytes or pluripotent stem cells.
  • the cryoprotective agent according to the invention may comprise at least one additional cryoprotectant selected from the group consisting of acetamide, agarose, alginate, 1-analine, albumin such as human serum albumin, ammonium acetate, butanediol, chondroitin sulfate, chloroform, choline, diethylene glycol, dimethyl acetamide, dimethyl formamide, dimethyl sulfoxide (DMSO), erythritol, ethanol, ethylene glycol, formamide, glucose, glycerol, a-glycerophosphate, glycerol monoacetate, glycine, hydroxyethyl starch, inositol, lactose, magnesium chloride, magnesium sulfate, maltose, mannitol, mannose, methanol, methyl acetamide, methylformamide, methyl ureas, phenol, pluronic polyols, polyethylene glycol,
  • said additional cryoprotectant is ethylene glycol.
  • said additional cryoprotectant is DMSO.
  • an additional cryoprotectant such as ehtylene glycol is present in said agent in an amount from 5 % to 40 % w/w, such as from 5 % to 30 % w/w.
  • the cryoprotective agent may be substantially free of DMSO, e.g. free of DMSO.
  • the cryoprotective agent according to the invention may comprise a cryoprotectant as described herein such as carboxyalkyldextran as the only cryoprotectant.
  • cryoprotective agent is free of or substantially free of DMSO.
  • said cryoprotectant as described herein such as ca rboxya I ky I dextra n is the only cryoprotectant in the cryoprotective agent.
  • cryoprotective agent free or substantially free of DMSO may not require washing after thawing of the sample.
  • the thawed sample may then be directly suspended in a culture medium to immediately start a culturing process without having to wash the sample or may be directly used in a patient without a washing step that potentially leads to substantial cell loss.
  • Another advantage using a cryoprotective agent free of or substantially free of DMSO is that the sample may be exposed to the cryoprotectant for a longer period without damage, enabling a more efficient working process.
  • the cryoprotective agent further comprises at least one anti-freeze protein and/or anti-freeze glycoprotein such as in an amount of from 0.01 to 1 mg/mL of the cryoprotective agent.
  • An example of an anti-freeze glycoprotein is Type I AFP from longhorn sculpin, which is a single, long amphipathic alpha helix.
  • the cryoproteting agent or composition may comprise further substances for improving the viability of the sample.
  • IAPs IAPs
  • the cryoproteting agent or composition may also comprise a growth medium.
  • a growth medium comprising -catenin/P300 antagonist and an Activin/TGFp ligand, such as for example ID-8 in conjunction with Activin and TGF3, may be used.
  • This type of medium is especially useful for culturing of pluripotent stem cells, in particular embryonic stem cells as for example described in WO 2013/054112.
  • Another example is the standard knock-out medium comprising KnockOut Serum Replacement, DMEM/F12 with GlutaMAXTM supplement, FGF, EAA and BME.
  • Another example is the mTSERTM system.
  • growth media depending on the sample to be cryopreserved is well known to the skilled person.
  • the cryoprotective agent as disclosed herein may be in the form of a powder such as a lyophilized or spray dried powder.
  • said cryoprotective agent is in the form of a solution.
  • the agent may thus further comprise a solvent such as for example sterile water.
  • said agent comprises from 30% to 70% w/w of said cryoprotectant, such as from 40% to 65% w/w or from 50% to 60% w/w of said cryoprotectant.
  • said agent comprises from 5 % to 50 % w/w of said cryoprotectant, such as from 5 % to 40 % w/w, such as from 5 % to 30 % of said cryoprotectant.
  • the sample such as cells, tissue or organs to be cryopreserved can also be in contact with a freezing compatible pH buffer comprised most typically of at least a basic salt solution, an energy source (for example, glucose) and a buffer capable of maintaining a neutral pH at low temperatures.
  • a freezing compatible pH buffer comprised most typically of at least a basic salt solution, an energy source (for example, glucose) and a buffer capable of maintaining a neutral pH at low temperatures.
  • DMEM Dulbecco's Modified Eagle Medium
  • cryopreservation composition comprising a cryoprotective agent as described herein, which cryopreservation composition further comprises a sample to be cryopreserved.
  • a further aspect disclosed herein is a cryopreserved composition
  • a cryopreserved composition comprising a cryoprotective agent and a sample which has been cryopreserved or is In the process of being
  • cryopreserved composition means either "a cryopreservation composition" which is in the process of being cryopreserved or already has been cryopreserved.
  • a further aspect disclosed herein is a cryopreserved composition
  • a cryopreserved composition comprising a growth medium or substrate for the sample to be cryopreserved.
  • the pH of the cryopreservation composition may be adjusted for example adjusting the pH of the cryopreservation composition to a pH of between 6.5 and 8.5, such as between 6.5 and 7.8, preferably to a pH 7.0 - 7.4.
  • a freezing compatible pH buffer comprised most typically of at least a basic salt solution, an energy source (for example, glucose) and a buffer capable of maintaining a neutral pH at low temperatures.
  • the sample is selected from the group consisting of organs, cells, and tissues such as mammalian.
  • the sample is organs, cells, blood or tissues.
  • Examples of such cells to be cryopreserved are in-vitro-cultured cells including primary cells, cell lines, in vitro-sorted cells including human blood cells, and fertilized eggs of animal and human origin. Further examples are sperm cells, embryonic stem cells, iPS iPSCs, mesenchymal stem cells, haemopoietic stem cells, neuronal stem cells, umbilical cord blood stem cells, hepatocytes, nerve cells, cardiomyocytes, vascular endothelial cells, vascular smooth muscle cells and blood cells.
  • the sample is cells selected from the group consisting of mesencymal stem cells, hematopoietic stem cells, embryonic stem cells, iPS iPSCs, keratinocytes, preferable hematopoietic stem cells such as CD34 positive blood stem cells, mesenchymal stem cells embryonic stem cells and iPSCs.
  • the sample is selected from the group consisting of mesenchymal stem cells and hematopoietic stem cells.
  • the cell is of animal or human origin. Examples of organs are lung, liver, kidney, heart, ovaries and pancreas.
  • tissues are tissues of bone marrow, skin, ovaries, testis, blood vessels, connective tissue, preferable tissues of ovaries and connective tissue.
  • the blood is selected from the group consisting of umbilical cord blood, and mobilized peripheral blood, preferable umbilical cord blood.
  • the sample is a cell-containing body fluid such as blood, menstrual fluid or amniotic fluid.
  • the cryoprotectant is typically present in the composition to be cryopreserved in an amount from 1 to 50 % w/w such as from 2 to 50 % w/w, such as from 4 to 45 % w/w, or from 6 to 20 % w/w, or from 6 to 12 % w/w, or preferably from 6 to 10% w/w, or more preferably from 7 to 9% w/w.
  • the cryoprotectant is present in the composition to be cryopreserved in an amount of at the most 60% w/w, such as in an amount of at the most 55% w/w, such as in an amount of at the most 50% w/w, such as in an amount of at the most 45% w/w, such as in an amount of at the most 40% w/w, such as in an amount of at the most 35% w/w.
  • the cryoprotectant is typically present in an amount of at the least 2% w/w, such as present in an amount of at the least 4% w/w, such as present in an amount of at the least 6% w/w, such as present in an amount of at the least 6% w/w, such as present in an amount of at the least 7% w/w.
  • the cryoprotectant is typically present in the composition to be cryopreserved in an amount of less than 40 % w/w, less than 30 % w/w such as from 5 % to 50 % w/w, such as 5 % to 40 % w/w, such as from 5 % to 30 % w/w of said cryoprotectant.
  • an additional cryoprotectant such as ethylene glycol is typically present in the composition to be cryopreserved in an amount less than 40 % w/w, less than 30 % w/w such as from 1-25% w/w.
  • an additional cryoprotectant such as ethylene glycol is typically present in the composition to be cryopreserved in an amount of 5 % to 30 % w/w, such as from 5 % to 25 % w/w of said additional cryoprotectant such as ethylene glycol.
  • composition to be cryoprotected comprises an additional cryoprotectant such as DMSO
  • additional cryoprotectant typically is present in an amount of less than 8 % w/w, such as from 1-8% w/w, such as for example in an amount below 5% w/w, such as below 4 % w/w such as from 1-4% w/w.
  • a sample is harvested, suspended in a storage solution, and then preserved by freezing.
  • the sample such as cells are to be used, they are thawed, for example, cells taken from human donor sources are brought back to the normal human body temperature (i.e., approximately 37° C), and then placed in a cell culture medium.
  • the sample is protected during cryopreservation by being brought into contact with a cryoprotective agent as described herein prior to freezing to the cryopreservation temperature.
  • a cryoprotective agent as described herein prior to freezing to the cryopreservation temperature.
  • the cells may be brought into contact with the cryoprotective agent by filling the appropriate wells of a plate to which the cells to be protected are attached, by suspending the cells In a solution of the cryoprotective agent or by adding the cryoprotective agent for example in freeze dried form to the cells, blood or organ already in a solution of for example buffer, or by resuspending the cell pellet after centrifugation In the cryoprotective agent bringing the cells into a solution etc.
  • the cells may be brought into contact with the cryoprotective agent by placing a cell-containing scaffold or biomaterial in the cryoprotective agent or by adding the cells in the cryoprotective solution to a scaffold/biomaterial.
  • the organ or tissue may be brought into contact with the
  • cryoprotective agent by filling the transplant container with the cryoprotective solution.
  • a method of cryopreserving a sample comprising the protection steps of bringing a sample to be cryopreserved into contact with a cryoprotective agent as defined herein to obtain a cryopreservation composition and subsequently reducing the temperature of the cryopreservation composition to a cryopreservation temperature.
  • a method of cryopreserving a composition as defined herein by reducing the temperature of said composition to a cryopreservation temperature is disclosed herein.
  • the rate of change from room temperature to 1-2 °C below the freezing point of the solution may have a major effect on ultimate viability if the cells are sensitive to thermal shock.
  • the sample Is normally induced to freeze either by the
  • ice crystal by touching the surface of the media with a cold probe, by mechanical vibration, or by rapidly lowering the temperature until ice nucleation occurs. Since freezing is an exothermic process, heat must be conducted away from the freezing solution. This may be done either by keeping the samples immersed in a liquid with a low freezing point or by providing a substantial heat sink. As ice forms in the extracellular media, more and more free water becomes bound in the ice phase. Cell membranes, being hydrophobic, act as a barrier for the nucleation of intracellular ice and therefore unfrozen cells are exposed to an increasingly hypertonic solution. The extracellular salt concentration increases as a consequence of water sequestration into ice. The unfrozen cells shrink due to the transport of water out of the cell in response to the osmotic imbalance between the intracellular and extracellular fluid phases. The sample is then cooled at a finite rate which must be optimized for each cell type.
  • the optimal rate of cooling is determined by the permeability of the cell membrane to water, the surface-to-volume ratio of the cell, along the type and concentration of cryoprotective additives in the cryoprotective agent as described herein.
  • the optimal cooling rate usually is between about 0.3 to 10 °C per minute.
  • Continuous cooling between about 4 °C and -80 °C is the most commonly used.
  • cryopreservation is the vitrification technology in which it is possible to obtain very fast cooling rates of 1000 °C - 2000 °C/min.
  • a specialized vitrification device containing the cryopreservation composition with the sample, is directly placed into liquid nitrogen.
  • the cryopreservation temperature is reached at a rate of 0.05- 15, such as 0.1-10, such as 0.2-8, such as 0.3-6, such as 0.4-4, such as 0.5-2°C per minute.
  • the cryopreservation temperature is reached at a rate of 500-3000, such as 800-2500, such as 1000-2000, such as 1200-1800 °C per minute.
  • the duration of viable cell storage at liquid nitrogen temperature is dependent predominantly on the rate of generation of free radicals caused by the cosmic ray background.
  • the half-life for mammalian embryos stored in liquid nitrogen has been estimated to be approximately 30,000 years. It is important not to allow frozen cells to warm above their storage temperature for even brief periods of time. Intermittent warming promotes rapid migratory recrystallization, which can damage cellular structure and decrease overall viability.
  • the sample are thawed after cryopreservation.
  • the optimal rate of thawing of the sample is dependent on the freezing conditions used and the specific sample to be preserved.
  • a rapid rate of warming is desirable.
  • Such rapid warming limits the growth of ice crystals in the frozen samples and is often an absolute requirement for high survival. With many tissues this warming can be accomplished by agitating the sample in a 37-42 °C water bath.
  • the rationale for rapid warming is that it limits the growth of ice crystals which were formed during cooling.
  • Some tissues may be sensitive to rapid warming. This is due to transient osmotic shock, because the cells are exposed to an extracellular hypertonic solution as the ice melts and are forced to rehydrate in order to maintain their osmotic equilibrium.
  • metabolic processes can be reactivated or brought up to normal levels by successive dilutions using serum or other high molecular weight polymers in the thawing medium.
  • cryoprotective agents which must be gradually diluted to return the cells to an isotonic media.
  • a stepwise dilution protocol is typically used. The dilution of the sample is normally carried out at preferably 37 °C, so as to reduce the effects of both osmotic shock and cryoprotectant toxicity.
  • the concentration of said cryoprotectant is from 4 to 45 % w/w, such as from 8 to 35 % w/w, such as from 10 to 25 % w/w, or from 12 to 23 % w/w, or preferably from 12 to 22 % w/w, or more preferably from 15 to 21 % w/w cryoprotectant.
  • the temperature of the sample in the cryopreservation composition is reduced to a cryopreservation temperature below -50°C, such as between -50°C to - 196°C, such as between -80°C to - 196°C.
  • the cryoprotective agent is used in a banking method. In one aspect, the cryoprotective agent is used in a clinical banking method. In one aspect, the cryoprotective agent is used in a mobilized peripheral blood banking method. In one aspect, the cryoprotective agent is used in a clinical banking method such as in stem cell transplantation for malignant diseases or in an organ transplantation. In one aspect, the cryoprotective agent is used in a mobilized peripheral blood banking method, marrow banking method or in an umbilical cord banking method.
  • the cryoprotective agent is used in a marrow banking method or in an umbilical cord banking method. In one aspect, the cryoprotective agent is used in a fat tissue banking method or in a dental pulp tissue banking method. In a further aspect, the cryoprotective agent is used in a reproduction banking method.
  • Embodiment 1 Use of a cryoprotectant selected from the group consisting of ca rboxya I ky I dextra n , hydrogenated carboxyalkyldextran, oxidated carboxyalkyldextran, ether of carboxyalkyldextran, ester of carboxyalkyldextran and partly oxidated/hydrogenated ca rboxya I ky Idextran or a combination thereof for cryopreserving a sample, and wherein said sample is selected from the group consisting of organs, cells, and tissues.
  • Embodiment 2 The use according to embodiment 1, wherein the cryoprotectant is hydrogenated carboxyalkyldextran, such as hydrogenated
  • Embodiment 3 The use according to embodiment 1, wherein the cryoprotectant is carboxyalkyldextran.
  • Embodiment 4 The use according to any one of embodiments 1-3, wherein the carboxyalkyldextran is carboxyCi_i 0 alkyldextran.
  • Embodiment 5 The use according to any one of embodiments 1-4, wherein the a Iky I is C 1-10 alkyl.
  • Embodiment 6 The use according to any one of embodiments 1-5, wherein the
  • Embodiment 7 Use of a cryoprotectant selected from the group consisting of carboxyalkyldextran, hydrogenated carboxyalkyldextran, oxidated carboxyalkyldextran, ether of carboxyalkyldextran, ester of carboxyalkyldextran and partly oxidated/hydrogenated ca rboxya I ky Idextra n or a combination thereof, wherein the a Iky I is methyl, for cryopreserving a sample, and wherein said sample is selected from the group consisting of organs, cells, and tissues.
  • a cryoprotectant selected from the group consisting of carboxyalkyldextran, hydrogenated carboxyalkyldextran, oxidated carboxyalkyldextran, ether of carboxyalkyldextran, ester of carboxyalkyldextran and partly oxidated/hydrogenated ca rboxya I ky Idextra n or a combination thereof, wherein the a Iky I is
  • Embodiment 8 The use according to any one of embodiments 1-7, wherein the cryoprotectant has a weight average molecular weight (M w ) of between 300 and 900,000 Da such as of between 300 and 700,000 Da.
  • Embodiment 9. The use according to any one of embodiments 1-8, wherein the cryoprotectant has a weight average molecular weight (M w ) of above 700,000 Da such as between 700.000 and 900,000 Da.
  • Embodiment 10 The use according to any one of embodiments 1-9, wherein the cryoprotectant has a weight average molecular weight (M w ) of between 300 and 500,000 Da.
  • M w weight average molecular weight
  • Embodiment 11 The use according to any one of embodiments 1-10, wherein the cryoprotectant has a weight average molecular weight (M w ) of between 300 and 15,000 Da.
  • M w weight average molecular weight
  • Embodiment 12 The use according to any one of embodiments 1-11, wherein the cryoprotectant has a weight average molecular weight (M w ) of between 300 and 9,500 Da.
  • Embodiment 13 The use according to any one of embodiments 1-12, wherein the carboxyalkyldextran has a weight average molecular weight (M w ) of between 300 and 700,000 Da such as between 300 and 500,000 Da.
  • Embodiment 14 The use according to any one of embodiments 1-13, wherein the carboxyalkyldextran has a weight average molecular weight (M w ) of between 300 and 9,500 Da.
  • M w weight average molecular weight
  • Embodiment 15 The use according to any one of embodiments 1- 14, wherein the carboxyalkyldextran has a weight average molecular weight (M w ) of between 1000 and 9,500Da.
  • M w weight average molecular weight
  • Embodiment 16 Use of a cryoprotectant selected from the group consisting of carboxyalkyldextran, hydrogenated carboxyalkyldextran, oxidated carboxyalkyldextran, ether of carboxyalkyldextran, ester of ca rboxya Iky Idextra n and partly oxidated/hydrogenated carboxyalkyldextran or a combination thereof, wherein the cryoprotectant has a weight average molecular weight (M w ) of between 300 and 9,500 Da, and wherein the alkyl is C,. i 0 alkyl, such as methyl, for cryopreserving a sample, and wherein said sample is selected from the group consisting of organs, cells, and tissues.
  • M w weight average molecular weight
  • cryoprotectant has a weight average molecular weight (M w ) of between 1000 and 9,500Da.
  • M w weight average molecular weight
  • Embodiment 18 The use according to any one of embodiments 1-17, wherein the cryoprotectant is carboxymethyl isomaltooligosaccharide having a weight average molecular weight of 850-1, 150 Da.
  • Embodiment 19 The use according to any one of embodiments 1-18, wherein the cryoprotectant is hydrogenated or oxidated carboxyalkyldextran such as hydrogenated carboxymethyl isomaltooligosaccharide having a weight average molecular weight of 850- 1,150 Da.
  • Embodiment 20 The use according to any one of embodiments 1-19, wherein the cryoprotectant has a weight average molecular weight (M w ) of between 300 and 15,000 Da such as approximately 6000 Da.
  • Embodiment 21 The use according to any one of embodiments 1-20, wherein the cryoprotectant is hydrogenated ca rboxya Iky Idextra n such as hydrogenated
  • carboxymethyldextran having a weight average molecular weight of 300-15,000 Da.
  • Embodiment 22 The use according to any one of embodiments 1-21, wherein the cryoprotectant has a content of carboxy groups of above 1 % w/w, such as above 2 % w/w, such as between 1- 15 % w/w, or such as between 5-12 % w/w determined by direct titration using for example sodium hydroxide.
  • the cryoprotectant has a content of carboxy groups of above 1 % w/w, such as above 2 % w/w, such as between 1- 15 % w/w, or such as between 5-12 % w/w determined by direct titration using for example sodium hydroxide.
  • Embodiment 23 The use according to any one of embodiments 1-22, wherein the cryoprotectant has a content of carboxy groups between 1- 7 % w/w determined by direct titration using for example sodium hydroxide.
  • Embodiment 24 The use according to any one of embodiments 1-23, wherein the cryoprotectant such as carboxyalkyldextran has a content of carboxy groups of above 3 % w/w, such as above 4 % w/w, such as for example 4-7 % w/w determined by direct titration using for example sodium hydroxide.
  • the cryoprotectant such as carboxyalkyldextran has a content of carboxy groups of above 3 % w/w, such as above 4 % w/w, such as for example 4-7 % w/w determined by direct titration using for example sodium hydroxide.
  • Embodiment 25 The use according to any one of embodiments 1-24, wherein the cryoprotectant such as carboxyalkyldextran is prepared by using hydrogenated d extra n or hydrogenated isomaltooligosaccharide or the corresponding polysaccharide having a weight average molecular weight (M w ) of between 300 Da to 900,000 Da such as between 1000 and 900,000 as a starting material.
  • Embodiment 26 The use according to any one of embodiments 1-25, wherein the starting material has a weight average molecular weight (M w ) of between 1000 and 7000 Da, such as between 1650 and 6000 Da, such as between 2000 and 5000 Da.
  • Embodiment 27 The use according to any one of embodiments 1-26, wherein said starting material has a polydispersity of > 1 and ⁇ 5.
  • Embodiment 28 The use according to any one of embodiments 1-27, wherein said sample is selected from the group consisting of mammalian organs, mammalian cells, and mammalian tissues.
  • Embodiment 29 The use according to any one of embodiments 1-28, wherein said sample is cells.
  • Embodiment 30 The use according to any one of embodiments 1-29, wherein said sample is non-mammalian eukaryotes, bacteria, archea.
  • Embodiment 31 The use according to any one of embodiments 1-30, wherein said sample is mammalian cells.
  • Embodiment 32 The use according to any one of embodiments 1-31, wherein said mammalian cells are selected from the group consisting of somatic cells, including all kind of tissue derived cells such as mesenchymal stem cells, tissue-specific progenitor cells, keratinocytes, fibroblasts, chondrocytes, bone cells, or cardiomyocytes; blood derived cells such as hematopoietic stem cells, macrophages, plates, erythrocytes; or stem cells, including all types of pluripotent cells, totipotent cells and unipotent cells, and germ layer cells.
  • tissue derived cells such as mesenchymal stem cells, tissue-specific progenitor cells, keratinocytes, fibroblasts, chondrocytes, bone cells, or cardiomyocytes
  • blood derived cells such as hematopoietic stem cells, macrophages, plates, erythrocytes
  • stem cells including all types of pluripotent cells, totipotent cells and
  • Embodiment 33 The use according to any one of embodiments 1-32, wherein said mammalian cells are selected from the group consisting of mesenchymal stem cells, hematopoietic stem cells, pluripotent stem cells.
  • Embodiment 34 The use according to any one of embodiments 1-33, wherein said mammalian cells are selected from the group consisting of mesenchymal stem cells such as induced pluripotent stem cells (iPSC) and embryonic stem cells (ESC).
  • iPSC induced pluripotent stem cells
  • ESC embryonic stem cells
  • Embodiment 35 The use according to any one of embodiments 1-34, wherein said sample is mammalian tissue such as ovarian tissue.
  • Embodiment 36 The use according to any one of embodiments 1-35, wherein said sample is a mammalian organ such as ovaries.
  • Embodiment 37 The use according to any one of embodiments 1-36, wherein said cryoprotectant such as carboxyalkyldextran is used in combination with another
  • cryoprotectant such as DMSO or ethylene glycol.
  • Embodiment 38 The use according to any one of embodiments 1-37, where said cryoprotectant such as carboxyalkyldextran is used for cryopreserving a sample in a cryopreservation composition having a pH of between 6.5 and 8.5, such as between 6.5 and 7.8.
  • said cryoprotectant such as carboxyalkyldextran
  • Embodiment 39 The use according to any one of embodiments 1-38, where said use further comprises using any serum component of human, bovine, equine, or canine origin in the cryopreservation composition.
  • Embodiment 40 The use according to any one of embodiments 1-39, where said use further comprises using albumin.
  • Embodiment 41 The use according to any one of embodiments 1-40, where said use further comprises using human serum albumin.
  • Embodiment 42 The use according to any one of embodiments 1-41, wherein said use comprises further using ethylene glycol and human serum albumin .
  • Embodiment 43 The use according to any one of embodiments 1-42, where said use further comprises using heparin .
  • Embodiment 44 The use according to any one of embodiments 1-43, where said use further comprises using said cryoprotectant in an aqueous solution .
  • Embodiment 45 A cryoprotective agent comprising a cryoprotectant selected from the group consisting of carboxyalkyldextran, hydrogenated carboxyalkyldextran, oxidated carboxyalkyldextran, ether of carboxyalkyldextran, ester of carboxyalkyldextran and partly oxidated/hydrogenated carboxyalkyldextran or a combination thereof.
  • Embodiment 46 The cryoprotective agent according to embodiment 45, wherein the cryoprotectant is carboxyalkyldextran or hydrogenated carboxyalkyldextran.
  • Embodiment 47 The cryoprotective agent according to embodiment 45, wherein the cryoprotectant is hydrogenated carboxyalkyldextran.
  • Embodiment 48 A cryoprotective agent comprising carboxyalkyldextran.
  • Embodiment 49 The cryoprotective agent according to any one of embodiment 45-
  • carboxyalkyldextran is carboxyC ! - 10 a iky Idextra n.
  • Embodiment 50 The cryoprotective agent according to embodiment 49, wherein the d- ! oalkyl is methyl.
  • Embodiment 51 The cryoprotective agent according to any one of embodiments.
  • Embodiment 53 The cryoprotective agent according to any one of embodiments
  • Embodiment 54 A cryoprotective agent selected from the group consisting of ca rboxya I ky Idextra n , hydrogenated carboxyalkyldextran, oxidated carboxyalkyldextran, ether of carboxyalkyldextran, ester of carboxyalkyldextran and partly oxidated/hydrogenated carboxyalkyldextran or a combination thereof, wherein the alkyl is methyl.
  • Embodiment 55 The cryoprotective agent according to any one of embodiments.
  • cryoprotectant has a weight average molecular weight (M w ) of between 300 and 900,000 Da such as of between 300 and 700,000 Da.
  • Embodiment 56 The cryoprotective agent according to any one of embodiments
  • cryoprotectant has a weight average molecular weight (M w ) of above 700,000 Da such as between 700.000 and 900,000 Da.
  • Embodiment 57 The cryoprotective agent according to any one of embodiments
  • cryoprotectant has a weight average molecular weight (M w ) of between 300 and 500,000 Da.
  • M w weight average molecular weight
  • cryoprotectant has a weight average molecular weight (M w ) of between 300 and 9,500 Da.
  • M w weight average molecular weight
  • cryoprotectant such as carboxyalkyldextran has a weight average molecular weight (M w ) of between 300 and 900,000 Da such as of between 300 and 700,000 Da.
  • M w weight average molecular weight
  • Embodiment 60 The cryoprotective agent according to any one of embodiments
  • cryoprotectant such as carboxyalkyldextran has a weight average molecular weight (M w ) of between 300 and 500,000 Da.
  • Embodiment 61 The cryoprotective agent according to any one of embodiments 45-60, wherein the cryoprotectant has a weight average molecular weight (Mw) of between 300 and 15,000 Da.
  • Mw weight average molecular weight
  • Embodiment 62 The cryoprotective agent according to any one of embodiments
  • cryoprotectant such as carboxyalkyldextran has a weight average molecular weight (M w ) of between 1000 and 9,500Da.
  • a cryoprotective agent comprising a cryoprotectant selected from the group consisting of carboxyalkyldextran, hydrogenated carboxyalkyldextran, oxidated carboxyalkyldextran, ether of carboxyalkyldextran, ester of carboxyalkyldextran and partly oxidated/hydrogenated carboxyalkyldextran or a combination thereof, wherein the cryoprotecta t has a weight average molecular weight (M w ) of between 300 and 9,500 Da, wherein the a Iky I is C 1-10 alkyl, such as methyl.
  • M w weight average molecular weight
  • Embodiment 64 The cryoprotective agent according to any one of embodiments 45-63, wherein the cryoprotectant has a weight average molecular weight (M w ) of between 1000 and 9,500Da.
  • M w weight average molecular weight
  • Embodiment 65 The cryoprotective agent according to any one of embodiments
  • cryoprotectant is carboxymethyl isomaltooligosaccharide having a weight average molecular weight of 850- 1,150 Da.
  • Embodiment 66 The cryoprotective agent according to any one of embodiments
  • cryoprotectant is hydrogenated or oxidated carboxyalkyldextran such as hydrogenated carboxymethyl isomaltooligosaccharide having a weight average molecular weight of 850-1,150 Da.
  • Embodiment 67 The cryoprotective agent according to any one of embodiments 45-66, wherein said cryoprotectant is prepared by using hydrogenated dextran or hydrogenated isomaltooligosaccharide or the corresponding polysaccharide having a weight average molecular weight (M w ) of between 1000 Da to 900,000 Da such as between 1000 to 700,000 as a starting material.
  • Embodiment 68 The cryoprotective agent according to embodiment 67, wherein the starting material has a weight average molecular weight (M w ) of between 1000 and 7000 Da, such as between 1650 and 6000 Da, such as between 2000 and 5000 Da.
  • Embodiment 69 The cryoprotective agent according to any one of embodiments 45-68, wherein said starting material has a polydispersity of > 1 and ⁇ 5.
  • Embodiment 70 The cryoprotective agent according to any one of embodiments
  • cryoprotectant has a content of carboxy groups of above 1 % w/w, such as above 2 % w/w determined by direct titration using for example sodium hydroxide.
  • Embodiment 71 The cryoprotective agent according to any one of embodiments
  • cryoprotectant has a content of carboxy groups between 1- 7 % w/w determined by direct titration using for example sodium hydroxide.
  • Embodiment 72 The cryoprotective agent according to any one of embodiments
  • cryoprotectant has a content of carboxy groups between 1- 15 % w/w, such as between 5-12 % w/w determined by direct titration.
  • Embodiment 73 The cryoprotective agent according to any one of embodiments 45-72, wherein the cryoprotectant such as carboxyalkyldextran has a content of carboxy groups of above 3 % w/w, such as above 4 % w/w, such as for example between 4-7% w/w determined by direct titration using for example sodium hydroxide.
  • the cryoprotectant such as carboxyalkyldextran has a content of carboxy groups of above 3 % w/w, such as above 4 % w/w, such as for example between 4-7% w/w determined by direct titration using for example sodium hydroxide.
  • Embodiment 74 The cryoprotective agent according to any one of embodiments 45-73 for cryopreserving a sample, and wherein said sample is selected from the group consisting of organs, cells, and tissue such as selected from the group consisting of mammalian organs, mammalian cells, and mammalian tissues.
  • Embodiment 75 The cryoprotective agent according to any one of embodiments
  • Embodiment 76 The cryoprotective agent according to any one of embodiments 45-75 for cryopreserving a sample, wherein said sample is functional after cryopresevation .
  • Embodiment 77 The cryoprotective agent to any one of embodiments 45-76, wherein said sample is an organ, which organ is functional as measured by physiological function of said organ after cryopreservation, and/or wherein said sample is tissue, which tissue is functional as measured by ability of such tissue to integrate with surrounding tissue and/or wherein said sample is cells, which cells are functional as measured by viability of said cells after cryopreservation.
  • Embodiment 78 The cryoprotective agent according to any one of embodiments 45-78, comprising at least one additional cryoprotectant selected from the group consisting of acetamide, agarose, alginate, 1-analine, albumin, ammonium acetate, butanediol, chondroitin sulfate, chloroform, choline, diethylene glycol, dimethyl acetamide, dimethyl formamide, dimethyl sulfoxide (DMSO), erythritol, ethanol, ethylene glycol, formamide, glucose, glycerol, a-glycerophosphate, glycerol monoacetate, glycine, hydroxyethyl starch, inositol, lactose, magnesium chloride, magnesium sulfate, maltose, mannitol, mannose, methanol, methyl acetamide, methylformamide, methyl ureas, phenol, pluronic polyols, poly
  • Embodiment 79 The cryoprotective agent according to embodiment 78, wherein said additional cryoprotectant is ethylene glycol.
  • Embodiment 80 The cryoprotective agent according to embodiment 78, wherein said additional cryoprotectant is DMSO.
  • Embodiment 81 The cryoprotective agent according to any one of embodiments
  • Embodiment 82 The cryoprotective agent according to embodiment 81, which is free of DMSO.
  • 45-82 comprising a cryoprotectant as defined in embodiment 1 as the only cryoprotectant.
  • Embodiment 84 The cryoprotective agent according to any one of embodiments 45-83, wherein said agent is in the form of a powder.
  • Embodiment 85 The cryoprotective agent according to any one of embodiments.
  • Embodiment 87 The cryoprotective agent according to any one of embodiments
  • said agent comprises from 30 % to 70 % w/w of said cryoprotectant, such as from 40 % to 65 % w/w or from 50 % to 60 % w/w of said cryoprotectant.
  • Embodiment 88 The cryoprotective agent according to any one of embodiments
  • said agent comprises from 30 % to 70 % w/w of said additional
  • cryoprotectant such as from 40 % to 65 % w/w or from 50 % to 60 % w/w of said additional cryoprotectant.
  • Embodiment 89 The cryoprotective agent according to any one of embodiments
  • said agent comprises from 5 % to 50 % w/w, such as 5 % to 40 % w/w, such as from 5 % to 30 % w/w of said cryoprotectant.
  • Embodiment 90 The cryoprotective agent according to any one of embodiments.
  • cryoprotective agent comprises from 5 % to 30 % w/w, such as from 5 % to 25 % w/w of said additional cryoprotectant such as ethylene glycol.
  • said additional cryoprotectant such as ethylene glycol.
  • 45-90 further comprising a growth medium or substrate for a sample to be cryopreserved.
  • Embodiment 92 The cryoprotective agent according to any one of embodiments
  • IAPs Insulants of apoptosis
  • ROCK rho-associated protein kinase
  • any growth factor such as EGF, FGF, PDGF, IGF, EPO, BDNF, TGF, TNF and/or VEGF.
  • Embodiment 93 The cryoprotective agent according to any one of embodiments
  • 45-93 comprising albumin in a concentration of less than 40 % (w/w) .
  • Embodiment 95 The cryoprotective agent according to any one of embodiments
  • 45-94 comprising human serum albumin in a concentration of less than 40 % (w/w).
  • Embodiment 96 The cryoprotective agent according to any one of embodiments
  • Embodiment 97 The cryoprotective agent according to any one of embodiments
  • cryoprotectant is sterile.
  • Embodiment 98 The cryoprotective agent according to any one of embodiments
  • Embodiment 99 A cryopreservation composition comprising a cryoprotective agent as defined in any one of embodiments 45-98, said cryopreservation composition further comprising a sample to be cryopreserved.
  • Embodiment 100 The cryopreservation composition according to embodiment 99, wherein the sample is selected from the group consisting of organs, cells such as isolated cells or cell-containing bodily fluids for example blood, and tissues.
  • Embodiment 101 The cryopreservation composition according to embodiment 100, wherein the sample is selected from the group consisting of mammalian organs, mammalian cells, and mammalian tissues, such as a sample selected from the group consisting of mammalian organs, mammalian cells, and mammalian tissues for transplantation.
  • Embodiment 102 The cryopreservation composition according to any one of embodiments 99-101, wherein said sample is cells selected from the group consisting of somatic cells, including all kind of tissue derived cells such as mesenchymal stem cells, tissue-specific progenitor cells, keratinocytes, fibroblasts, chondrocytes, bone cells, or cardiomyocytes, blood derived cells such as hematopoietic stem cells, macrophages, plates, erythrocytes, or stem cells, including all types of pluripotent cells, totipotent cells and unipotent cells, and germ layer cells.
  • tissue derived cells such as mesenchymal stem cells, tissue-specific progenitor cells, keratinocytes, fibroblasts, chondrocytes, bone cells, or cardiomyocytes
  • blood derived cells such as hematopoietic stem cells, macrophages, plates, erythrocytes, or stem cells, including all types of pluripotent cells,
  • cryopreservation composition according to any one of embodiments 99-102, wherein said sample is cells selected from the group consisting of keratinocytes, fibroblasts, mesenchymal stem cells, macrophages, and hematopoietic stem cells such as CD34 positive blood stem cells.
  • Embodiment 104 The cryopreservation composition according to any one of embodiments 99-103, wherein said sample is tissue selected from the group consisting of ovarian tissue, testicular tissue, umbilical cord tissue, placental tissue, connective tissue, cardiac tissue, tissue from muscle, bone, and cartilage tissue, endocrine tissue, and neural tissue.
  • Embodiment 105 Embodiment 105.
  • cryopreservation composition according to any one of embodiments 99- 104, wherein said sample is a cell-containing bodily fluid selected from the group consisting of blood such as umbilical cord blood, peripheral blood, and mobilized peripheral blood, amniotic fluid, semen, cerebrospinal fluid, menstrual fluid blood, and bone marrow aspirates.
  • Embodiment 106 The cryopreservation composition according to any one of embodiments 99-105, wherein said sample is an organ selected from the group consisting of lung, heart, kidney, liver, umbilical cord and ovaries.
  • Embodiment 107 The cryopreservation composition according to any one of embodiments 99-106, wherein said mammalian cells are selected from the group consisting of mesenchymal stem cells, hematopoietic stem cells, pluripotent stem cells.
  • Embodiment 108 The cryopreservation composition according to any one of embodiments 99- 107, wherein said mammalian cells is selected from the group consisting of mesenchymal stem cells such as induced pluripotent stem cells (iPSC) and embryonic stem cells (ESC).
  • iPSC induced pluripotent stem cells
  • ESC embryonic stem cells
  • Embodiment 109 The cryopreservation composition according to any one of embodiments 99- 108, wherein said sample is mammalian tissue such as ovarian tissue.
  • Embodiment 110 The cryopreservation composition according to any one of embodiments 99- 109, wherein said sample is a mammalian organ such as ovaries.
  • Embodiment 111 The cryopreservation composition according to any one of embodiments 99-111 comprising said cryoprotectant in an amount from 1 to 50 % w/w such as from 2 to 50 % w/w, or from 4 to 45 % w/w, or from 6 to 12 % w/w, or preferably from 6 to 10 % w/w, or more preferably from 7 to 9 % w/w.
  • Embodiment 112 The cryopreservation composition according to any one of embodiments 99-111, comprising said cryoprotectant in an amount of less than 40 % w/w, less than 30 % w/w such as from 5 % to 50 % w/w, such as 5 % to 40 % w/w, such as from 5 % to 30 % w/w of said cryoprotectant.
  • Embodiment 113 The cryopreservation composition according to any one of embodiments 99-112, wherein said composition comprises an additional cryoprotectant in an amount of less than 40 % w/w, less than 30 % w/w such as from 1-25% w/w, or such as from 5 % to 30 % w/w, or such as from 5 % to 25 % w/w.
  • Embodiment 114 The cryopreservation composition according to any one of embodiments 99-113, wherein said composition comprises DMSO in an amount of less than 20 % w/w, such as from 1-15 % w/w.
  • Embodiment 115 The cryopreservation composition according to any one of embodiments 99-114, wherein said composition comprises an additional cryoprotectant such as ethylene glycol in an amount of 40 % w/w, such as less than 40 % w/w, less than 30 % w/w such as from 1-25 % w/w.
  • an additional cryoprotectant such as ethylene glycol in an amount of 40 % w/w, such as less than 40 % w/w, less than 30 % w/w such as from 1-25 % w/w.
  • Embodiment 116 The cryopreservation composition according to any one of embodiments 99-115, wherein said sample is functional after cryopreservation.
  • Embodiment 117 The cryopreservation composition according to any one of embodiments 99-116, wherein said composition comprises DMSO in an amount of less than 20 % w/w, less than 15 % w/w such as from 1-12 % w/w.
  • Embodiment 118 The cryopreservation composition according to any one of embodiments 99-117, wherein said composition comprises ethylene glycol in an amount of less than 40 % w/w, less than 30 % w/w such as from 1-25 % w/w.
  • Embodiment 119 The cryopreservation composition according to any one of embodiments 99-118, wherein said composition comprises albumin in a concentration of less than 40 % (w/w).
  • Embodiment 120 The cryopreservation composition according to any one of embodiments 99-119, wherein said composition comprises human serum albumin in a concentration of less than 40 % (w/w).
  • Embodiment 121 The cryopreservation composition according to any one of embodiments 99-120, wherein said composition comprises heparin in a concentration of less than 2 % (w/w).
  • Embodiment 122 The cryopreservation composition according to any one of embodiments 99-121, wherein said composition comprises is sterile.
  • Embodiment 123 The cryopreservation composition according to any one of embodiments 99-122, which is in the form of an aqueous solution.
  • the cryopreservation composition according to any one of embodiments 99-123 having a pH of between 6.5 and 8.5, such as between 6.5 and 7.8, preferably at a pH of between 7.0 and 7.4.
  • Embodiment 125 A method of cryopreserving a sample, comprising bringing a sample to be cryopreserved into contact with a cryoprotective agent as defined in any one of embodiments 45-98 to obtain a cryopreservation composition and subsequently reducing the temperature of the cryopreservation composition to a cryopreservation temperature.
  • Embodiment 126 A method of cryopreserving a composition as defined in any one of embodiments 99-124 by reducing the temperature of said composition to a
  • Embodiment 127 The method according to any one of embodiments 125-126, wherein the cryopreservation temperature is reached at a rate of 0.05-15, such as 0.1-10, such as 0.2-8, such as 0.3-6, such as 0.4-4, such as 0.5-2 °C per minute.
  • Embodiment 128 The method according to any one of embodiments 125-127, wherein the concentration of said cryoprotectant is from 4 to 20 % w/w such as from 5 to 15 % w/w, or from 6 to 12 % w/w, or preferably from 6 to 10 % w/w, or more preferably from 7 to 9 % w/w.
  • Embodiment 129 The method according to any one of embodiments 125-128, wherein the temperature of the sample in the cryopreservation composition is reduced to a temperature below - 50°C, such as between - 50°C to - 196°C, such as -80°C to -196°C.
  • Embodiment 130 The method according to any one of embodiments 125-129, wherein the sample is thawed after cryopreservation.
  • Embodiment 131 The method according to any one of embodiments 125-130, wherein said sample is functional after cryopreservation.
  • Embodiment 132 The method according to any one of embodiments 125-131, wherein the sample to be cryopreserved is selected from the group consisting of organs, cells, and tissues, such as mammalian organs, mammalian cells, and mammalian tissues, preferably mammalian cells.
  • Embodiment 133 The method according to any one of embodiments 125-132, which is in a clinical banking method.
  • Embodiment 134 The method according to any one of embodiments 125-133, which is in a banking method such as a mobilized peripheral blood banking method, marrow banking method, a fat tissue banking method, a dental pulp tissue banking method, a reproduction banking method or in an umbilical cord banking method.
  • a banking method such as a mobilized peripheral blood banking method, marrow banking method, a fat tissue banking method, a dental pulp tissue banking method, a reproduction banking method or in an umbilical cord banking method.
  • Embodiment 135. The method according to any one of embodiments 125-134, wherein said sample is brought into contact with the cryoprotective agent by placing a cell- containing scaffold or biomaterial in the cryoprotective agent or by adding the cells in the cryoprotective solution to a scaffold/biomaterial.
  • Embodiment 136 The method according to any one of embodiments 125-135, wherein said sample is brought into contact with the cryoprotective agent by placing a cell- containing scaffold or biomaterial in the cryoprotective agent or by adding the cells in the cryoprotective solution to a scaffold/biomaterial.
  • the hydrolysis is monitored chromatographically using gel permeation chromatography (GPC), and is terminated by cooling when the molecular weight of the material being hydrolysed is estimated to have achieved the desired value, i.e. a weight average molecular weight of 850-1, 150 Daltons.
  • GPC gel permeation chromatography
  • the content of isomaltooligosaccharide is determined by optical rotation (a D 20 ⁇ 200) to be 915 kg, and the amount of reducing sugar is determined by use of Somogyi's reagent to be 22.5 % w/w.
  • AUPW Area under peak (M w )
  • the reducing sugar is measured to be 22.5 % w/w.
  • This isomaltooligosacharide is also named pentaisomaltose in this application.
  • AUPW Area under peak (M w )
  • isomaltooligosahharide is also named pentaisomaltoside in this applicaiton.
  • the finished product, hydrogenated carboxymethyl dextran contains 6.6 % carboxylic acid groups and has a specific rotation, measured in a 1 % w/w solution, of 156°.
  • Preparation Example 4 32.5 kg hydrogenated dextran having the molecular weight as indicated in below table 4 or Hydrogenated Isomoltooligosaccharide 1, containing less than 1.5 % w/w reducing end groups, is mixed with 30.4 kg of sodium hydroxide (27% w/w) and 32.5 kg of water.
  • cryopreservation agent used in the following examples were prepared by aseptically solubilizing/diluting the cryoprotectant (such as DMSO, human serum albumin (HSA), hydrogenated carboxymethyldextran, ethylene glycol) in growth medium (mTeSRl + penicillin/streptomycin) to the desired final concentration (e.g. DMSO 10 % w/w, ethylene glycol (EG) 20 % w/w, hydrogenated carboxymethyldextran 20 % w/w). Before use for cryopreservation of a sample, the cryopreservation composition was pH adjusted to pH 7.0 - 7.4 using a laboratory pH-meter.
  • the cryopreservation composition was pH adjusted to pH 7.0 - 7.4 using a laboratory pH-meter.
  • IPCs Induced pluripotent stem cells
  • vials containing cells were incubated in a 37°C water bath until the cells were almost thawed. 5 ml growth medium were added and cells were collected by spinning.
  • Fig. 1 and Fig. 2 Survival of iPS cells after freezing and thawing and number of cells after 7 days of proliferation is shown in Fig. 1 and Fig. 2.
  • the results show high survival for hydrogenated carboxymethyldextran (HCMD 5) in combination with 10 % w/w DMSO or 20% w/w ethylene glycol, but also with 10 % w/w DMSO alone. 20 % w/w ethylene glycol alone does not perform as well, whereas HCMD 5 alone also has a fairly high degree of survival. Looking at the ability of the cells to adhere and start proliferating, it is clear that freezing with HCMD 5 in combination with either 10 % w/w DMSO or 20 % w/w ethylene glycol largely increases the proliferative ability of the cells.
  • Human iPS cells were grown under standard conditions on matrigel coated surfaces in mtesrl complete medium from stemcell technologies (growth medium). Passage and harvesting of cells was done with an EDTA (0.2 % w/w) containing solution. After harvest, cells were collected by spinning and resuspended directly into the
  • vials containing cells were incubated in a 37°C water bath until the cells were almost thawed. 5 ml growth medium were added and cells were collected by spinning.
  • Fig. 3 demonstrate that human iPS cells survive cryopreservation with HCMD 1, HCMD 2.5, and CMD 5 as the only cryoprotectant present. Although the survival rate is lower than the standard cryopreservation solution containing 10 % w/w DMSO it is significant higher than a cryopreservation solution containing another standard cryoprotectant, ethylene glycol. It is also demonstrated that HCMD 5 is the most efficient HCMD in protecting the cells from damage under the cryopreservation process.
  • EXAMPLE 4 iPS cells were treated as described in example 2 and the experimental and analytical conditions were also as described in example 1.
  • Fig. 4 demonstrate that human IPS cells survive cryopreservation with the HCMDs and ethylene glycol as cryoprotectants.
  • Using the HCMD 5 and ethylene glycol results in the same survival rate as the standard DMSO based cryopreservation method. It is also demonstrated that all HCMDs have an additive cryoprotectant effect compared to ethylene glycol used alone.
  • iPSC lines were seeded and as exemplified on Fig . 5 resulted in proliferative and viable iPSC lines capable of being expanded .
  • EXAMPLE 5 iPS cells were treated as described in example 2 and the experimental and analytical conditions were also as described in example 1 added the additive HSA as indicated on
  • Fig. 6 demonstrate that human iPS cells survive cryopreservation with HCMDs, ethylene glycol and HSA as cryoprotectants.
  • HCMD5 combined with HSA and EG results in improved survival compared to DMSO alone.

Abstract

La présente invention concerne un agent cryoprotecteur comprenant un cryoprotecteur sélectionné dans le groupe constitué de carboxyalkyldextrane, de carboxyalkyldextrane hydrogéné, de carboxyalkyldextrane oxydé, d'éther de carboxyalkyldextrane, d'ester de carboxyalkyldextrane et de carboxyalkyldextrane partiellement oxydé/hydrogéné ou d'une combinaison de ceux-ci, des compositions cryoprotectrices et cryoconservées, leurs utilisations et des procédés de cryoconservation.
PCT/EP2015/057047 2014-04-01 2015-03-31 Agent cryoprotecteur, compositions cryoprotectrices et cryoconservées, leurs utilisations et procédés de cryoconservation WO2015150394A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP14163057.4 2014-04-01
EP14163057 2014-04-01
EP14170441 2014-05-28
EP14170441.1 2014-05-28
EP14171837.9 2014-06-10
EP14171837 2014-06-10

Publications (1)

Publication Number Publication Date
WO2015150394A1 true WO2015150394A1 (fr) 2015-10-08

Family

ID=52774254

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2015/057047 WO2015150394A1 (fr) 2014-04-01 2015-03-31 Agent cryoprotecteur, compositions cryoprotectrices et cryoconservées, leurs utilisations et procédés de cryoconservation

Country Status (1)

Country Link
WO (1) WO2015150394A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016076428A1 (fr) * 2014-11-14 2016-05-19 日本赤十字社 Procédé et solution pour la cryoconservation de sang de cordon ombilical et de sang périphérique
CN105660606A (zh) * 2016-03-10 2016-06-15 广州赛莱拉干细胞科技股份有限公司 一种细胞冻存液
CN110381962A (zh) * 2016-12-21 2019-10-25 孙崇谨 用于血浆蛋白的活性保存的新颖方法
EP3520746A4 (fr) * 2016-09-30 2020-05-06 Taipei Veterans General Hospital Agent antigel pour protéger un tissu biologique pendant un traitement par congélation et son procédé de préparation
CN112245394A (zh) * 2020-10-21 2021-01-22 成都柏奥特克生物科技股份有限公司 一种疫苗保护剂
JP2021192625A (ja) * 2012-11-30 2021-12-23 ファーマコスモス・ホールディング・アクティーゼルスカブPharmacosmos Holding A/S 凍結防止剤、凍結防止および凍結保存組成物、その使用ならびに凍結保存方法
CN113862332A (zh) * 2021-09-17 2021-12-31 浙江大学 琼脂糖在制备生物大分子冻干保护剂中的应用
US20220151221A1 (en) * 2014-07-09 2022-05-19 Genentech, Inc. pH ADJUSTMENT TO IMPROVE THAW RECOVERY OF CELL BANKS
JP2022536588A (ja) * 2019-04-30 2022-08-18 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 細胞の凍結保存のための組成物および方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6977249B1 (en) 1998-11-20 2005-12-20 Pharmacosmos Holding A/S Process for producing an iron-dextran compound, iron-dextran compound produced according to said process, pharmaceutical composition for prophylaxis or treatment of iron-deficiency and use of said compound for the preparation of parenterally administrable pharmaceutical composition
JP2007075540A (ja) * 2005-09-16 2007-03-29 Terumo Corp 生体組織置換性表面を持つ医療用材料
US20080176205A1 (en) * 2003-12-04 2008-07-24 University Of Utah Research Foundation Process and Formulation to Improve Viability of Stored Cells and Tissue
EP2484699A1 (fr) * 2009-09-28 2012-08-08 Terumo Kabushiki Kaisha Polysaccharide estérifié actif et son procédé de fabrication
WO2013054112A1 (fr) 2011-10-10 2013-04-18 Cell Guidance Systems Limited Milieux de culture pour cellules souches pluripotentes
WO2013107797A1 (fr) * 2012-01-17 2013-07-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Cryoconservation de cellules, tissus et organes
WO2014083169A1 (fr) * 2012-11-30 2014-06-05 Pharmacosmos A/S Agent cryoprotecteur, compositions cryoprotectrices et cryoconservées, leurs utilisations, et procédés de cryoconservation

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6977249B1 (en) 1998-11-20 2005-12-20 Pharmacosmos Holding A/S Process for producing an iron-dextran compound, iron-dextran compound produced according to said process, pharmaceutical composition for prophylaxis or treatment of iron-deficiency and use of said compound for the preparation of parenterally administrable pharmaceutical composition
US20080176205A1 (en) * 2003-12-04 2008-07-24 University Of Utah Research Foundation Process and Formulation to Improve Viability of Stored Cells and Tissue
JP2007075540A (ja) * 2005-09-16 2007-03-29 Terumo Corp 生体組織置換性表面を持つ医療用材料
EP2484699A1 (fr) * 2009-09-28 2012-08-08 Terumo Kabushiki Kaisha Polysaccharide estérifié actif et son procédé de fabrication
WO2013054112A1 (fr) 2011-10-10 2013-04-18 Cell Guidance Systems Limited Milieux de culture pour cellules souches pluripotentes
WO2013107797A1 (fr) * 2012-01-17 2013-07-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Cryoconservation de cellules, tissus et organes
WO2014083169A1 (fr) * 2012-11-30 2014-06-05 Pharmacosmos A/S Agent cryoprotecteur, compositions cryoprotectrices et cryoconservées, leurs utilisations, et procédés de cryoconservation

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
"Advances in polymer science", vol. 205, SPRINGER VERLAG, article "Polysaccharides II"
"European Pharmacopoeia", vol. 2, pages: 1816 - 1817
"European Pharmacopoeia", vol. 2, pages: 1816 - 1819
"Proc. Nati. Acad. Sci. USA", vol. 92, October 1995, MEDICAL SCIENCES, pages: 10119 - 10122
A I SLIVKIN ET AL: "SYNTHESIS AND ANTITUBERCULOUS ACTIVITY OF THE POLYMERIC FORMS OF ISONIAZID AND STREPTOMYCIN BASED ON CARBOXYMETHYLDEXTRAN ESTERS", PHARMACEUTICAL CHEMISTRY JOURNAL VOL ZHUMAL, vol. 33, no. 12, 1 January 1999 (1999-01-01), pages 661 - 664, XP055192221, Retrieved from the Internet <URL:http://rd.springer.com/content/pdf/10.1007/BF02974944.pdf> [retrieved on 20150528] *
A V KRASNIKOVA ET AL: "Acylation of Amino Acids with Dextran Derivatives", RUSSIAN JOURNAL OF APPLIED CHEMISTRY TRANSLATED FROM ZHURNAL PRIKLADNOI KHIMII, vol. 77, no. 5, 2004, pages 797 - 800, XP055192223, Retrieved from the Internet <URL:http://rd.springer.com/content/pdf/10.1023/B:RJAC.0000038816.74797.3a.pdf> [retrieved on 20150528] *
ASHWOOD-SMITH, M.J. ET AL., CRYOBIOLOGY, vol. 9, 1972, pages 441
COX ET AL., CELL TISSUE BANK, vol. 13, 2012, pages 203 - 215
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002740261, Database accession no. 1994-247695 *
DEXTRAN: "Handbook from Amersham BioSciences", pages: 35
ECHLIN, P. ET AL., J. MICROSC., vol. 110, 1977, pages 239
INT. ARCH. ALLERGY, vol. 41, 1971, pages 826 - 844
KWAN HWA PARK ET AL.: "Database CA, XP 002698458 a cryoprotectant containing fructooligosaccharide, isomaltooligosaccharide or galactooligosaccharide for surimi", J. KOREAN SOC. FOOD SCI. NUTR., vol. 30, no. 3, 2001, pages 565 - 568
ODAVIC, R. ET AL., EXPERIENTIA, vol. 36, 1980, pages 1122
RICHTER ET AL., INT. ARCH. ALLERGY, vol. 43, 1972, pages 252 - 268
SHU GUOWEI ET AL.: "Advanced Materials Research", vol. 328, 2012, TRANS TECH PUBLICATIONS LTD., pages: 454 - 457

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021192625A (ja) * 2012-11-30 2021-12-23 ファーマコスモス・ホールディング・アクティーゼルスカブPharmacosmos Holding A/S 凍結防止剤、凍結防止および凍結保存組成物、その使用ならびに凍結保存方法
US20220151221A1 (en) * 2014-07-09 2022-05-19 Genentech, Inc. pH ADJUSTMENT TO IMPROVE THAW RECOVERY OF CELL BANKS
WO2016076428A1 (fr) * 2014-11-14 2016-05-19 日本赤十字社 Procédé et solution pour la cryoconservation de sang de cordon ombilical et de sang périphérique
CN105660606A (zh) * 2016-03-10 2016-06-15 广州赛莱拉干细胞科技股份有限公司 一种细胞冻存液
CN105660606B (zh) * 2016-03-10 2018-04-03 广州赛莱拉干细胞科技股份有限公司 一种细胞冻存液
EP3520746A4 (fr) * 2016-09-30 2020-05-06 Taipei Veterans General Hospital Agent antigel pour protéger un tissu biologique pendant un traitement par congélation et son procédé de préparation
CN110381962A (zh) * 2016-12-21 2019-10-25 孙崇谨 用于血浆蛋白的活性保存的新颖方法
CN110381962B (zh) * 2016-12-21 2023-10-13 孙崇谨 用于血浆蛋白的活性保存的新颖方法
JP2022536588A (ja) * 2019-04-30 2022-08-18 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 細胞の凍結保存のための組成物および方法
CN112245394A (zh) * 2020-10-21 2021-01-22 成都柏奥特克生物科技股份有限公司 一种疫苗保护剂
CN112245394B (zh) * 2020-10-21 2022-10-11 成都柏奥特克生物科技股份有限公司 一种疫苗保护剂
CN113862332A (zh) * 2021-09-17 2021-12-31 浙江大学 琼脂糖在制备生物大分子冻干保护剂中的应用

Similar Documents

Publication Publication Date Title
JP6978644B2 (ja) 凍結防止剤、凍結防止および凍結保存組成物、その使用ならびに凍結保存方法
WO2015150394A1 (fr) Agent cryoprotecteur, compositions cryoprotectrices et cryoconservées, leurs utilisations et procédés de cryoconservation
CA3036391A1 (fr) Compositions et procedes de cryoconservation de cellules
JP7323290B2 (ja) 凍結保存組成物およびその使用方法
JP5867912B2 (ja) 細胞の凍結保存液および凍結保存方法
Freitas-Ribeiro et al. Long-term and short-term preservation strategies for tissue engineering and regenerative medicine products: state of the art and emerging trends
Ng et al. Sugar-assisted cryopreservation of stem cell-laden gellan gum–collagen interpenetrating network hydrogels
JP2023091093A (ja) 凍結保存液
US20230097342A1 (en) Cryoprotecting agent, cryoprotecting and cryopreserved compositions, uses thereof, and methods of cryopreservation
US20200375176A1 (en) Cryosolutions and uses thereof
JP7445611B2 (ja) 凍結保存液
US20200396985A1 (en) Preservation and cryopreservation media
Liu et al. Methods in biosynthesis and characterization of the antifreeze protein (AFP) for potential blood cryopreservation
JPWO2020166712A1 (ja) 凍結保存用高分子水溶液および生体試料を含む固化体
ES2871373T3 (es) Agente crioprotector, composiciones crioprotectoras y crioconservadas, usos de los mismos y métodos de crioconservación
JP2020130165A (ja) 生体試料を含む固化体
JP7459130B2 (ja) 融解液及びその調製方法並びに応用
CN115590018B (zh) 一种犬的临床用间充质干细胞冷藏保存液及其应用方法
JP2020130164A (ja) 凍結保存用高分子水溶液

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15712952

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase
122 Ep: pct application non-entry in european phase

Ref document number: 15712952

Country of ref document: EP

Kind code of ref document: A1